1. Home
  2. CSTL vs BW Comparison

CSTL vs BW Comparison

Compare CSTL & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$39.29

Market Cap

661.7M

Sector

Health Care

ML Signal

HOLD

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$5.49

Market Cap

544.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
BW
Founded
2007
1867
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Building Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
661.7M
544.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CSTL
BW
Price
$39.29
$5.49
Analyst Decision
Strong Buy
Buy
Analyst Count
6
2
Target Price
$42.83
$5.50
AVG Volume (30 Days)
370.2K
2.9M
Earning Date
11-03-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$343,530,000.00
$721,285,000.00
Revenue This Year
$1.69
N/A
Revenue Next Year
N/A
$4.85
P/E Ratio
N/A
N/A
Revenue Growth
10.15
80.30
52 Week Low
$14.59
$0.22
52 Week High
$42.18
$7.77

Technical Indicators

Market Signals
Indicator
CSTL
BW
Relative Strength Index (RSI) 58.67 50.83
Support Level $37.76 $4.73
Resistance Level $42.18 $5.44
Average True Range (ATR) 1.20 0.49
MACD -0.35 -0.07
Stochastic Oscillator 46.17 48.20

Price Performance

Historical Comparison
CSTL
BW

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: